Dyadic International, Inc. (DYAI)

Over the past six months, Dyadic International's stock price has declined, reaching $0.70 as of March 26, 2026. Key events include the Q3 2025 earnings call, analyst price target increases, and the Q4 2025 earnings call and 2025 financial results. Total revenue for 2025 decreased to $3.09 million, with a net loss of $7.36 million. Despite the revenue decline, the company highlighted its transition to a commercially focused biotechnology firm with new product launches and expanded partnerships.

Information specifically detailing the demand seasonality for Dyadic International's products and services is not explicitly available. Historical stock data shows that April has historically been the strongest month for DYAI, while July tends to be the weakest month. The seasonal pattern for DYAI has a consistency score of 37 (Poor), indicating that the pattern has not been highly reliable across different market conditions.

Dyadic International, Inc., now operating as Dyadic Applied BioSolutions, is a global biotechnology platform company focused on producing high-value proteins for non-therapeutic applications. The company operates in the healthcare sector, specifically the biotechnology industry, utilizing its C1 and Dapibus platforms to enable efficient production of recombinant proteins and enzymes. Key products include recombinant proteins and enzymes for life sciences, animal-free dairy proteins and food enzymes for food and nutrition, and industrial enzymes and proteins for bio-industrial applications. The company has transitioned to a commercially focused biotechnology firm.

Dyadic International, Inc. is a global biotechnology company headquartered in Jupiter, Florida, USA, with a satellite office in the Netherlands. The company actively participates in industry events worldwide to expand its global presence and foster international collaborations.

In mid-2025, Dyadic International rebranded itself as Dyadic Applied BioSolutions to emphasize its commercial biotechnology capabilities. The company's successful transition to a commercially focused biotechnology firm, marked by product launches and expanded partnerships, has been highlighted. Technological advancements through CRISPR licensing and manufacturing partnerships have also been noted as key progress points. The company's strategic rebranding and commercialization efforts indicate a proactive approach to shaping its brand reputation.

Dyadic International, Inc. has 41 institutional owners and shareholders, holding approximately 15.4% of the company's shares. Individual insiders hold about 16.4%, and the general public holds 68.2%. Major institutional owners include Apis Capital Advisors, LLC and Vanguard Group Inc. Joseph Hazelton, President and COO, is a notable individual insider.